Literature DB >> 25960812

Small intestinal bacterial overgrowth syndrome in children.

Katarzyna Siniewicz-Luzeńczyk1, Agnieszka Bik-Gawin1, Krzysztof Zeman1, Leokadia Bąk-Romaniszyn2.   

Abstract

INTRODUCTION: Small intestinal bacterial overgrowth syndrome (SIBO) is defined as an increased number of nonpathogenic bacteria over 10(5) organisms in 1 millilitre of small intestine content. The most common predisposing factors include, among others, gut motility disorders and chronic use of proton pump inhibitors. The results of recent studies indicate the importance of SIBO in gastrointestinal diseases. AIM: To assess the prevalence of SIBO in children with abdominal pain.
MATERIAL AND METHODS: One hundred children (59 girls and 41 boys) aged from 4 to 17 years (mean age: 10.47 ±3.73 years), hospitalised due to abdominal pain, were enrolled in the study. Hydrogen breath test (HBT) with lactulose was established among all patients. Expired air was analysed using a Gastrolyzer (Bedfont).
RESULTS: The HBT result was positive in 63 (63%) children with abdominal pain; including 40 girls (67.8%) and 23 boys (56.1%). The test was positive in the group of 29 (46%) children aged under 10 years and in the group of 34 (54%) children aged over 10 years. Among the patients who reported for the control study 88% achieved a normalisation of HBT after treatment.
CONCLUSIONS: The prevalence of positive HBT results in the group of patients with abdominal pain is over 60%. Small intestinal bacterial overgrowth syndrome should be considered as one of the causes of abdominal pain in children. The SIBO in children shows a good response to treatment.

Entities:  

Keywords:  abdominal pain; children; hydrogen breath test; small intestinal bacterial overgrowth syndrome

Year:  2015        PMID: 25960812      PMCID: PMC4411403          DOI: 10.5114/pg.2014.47494

Source DB:  PubMed          Journal:  Prz Gastroenterol        ISSN: 1895-5770


Introduction

Small intestinal bacterial overgrowth syndrome (SIBO) is defined as an increased number of nonpathogenic bacteria over 105 organisms in 1 millilitre of small intestine content [1-3]. The most common predisposing factors include gut motility disorders and chronic use of proton pump inhibitors [2, 4]. The SIBO is characterised by a large variety of clinical pictures [5, 6]. Symptoms of SIBO are directly associated with bacterial metabolism, intestinal mucosa damage that leads to impaired absorption of fat, proteins, carbohydrates, and fat-soluble vitamins [7, 8]. The most common and therefore most commonly reported symptoms of SIBO include diarrhoea, abdominal pain, and flatulence. Cases of weight loss, symptoms of iron deficiency anaemia, vitamin D deficiency, hypocalcaemia, and even osteoporosis as a late complication of SIBO are described in the literature [9, 10]. The course of SIBO is also considered to be completely asymptomatic [6]. The standardisation of the methods used in the diagnosis of SIBO is still under discussion. Some authors believe that the only method of diagnosing SIBO, regarded as the “gold standard”, is microbiological examination of the content sampled from the proximal part of the small intestine [11]. It is a direct method classified as an invasive one, as well as quite expensive [6, 8, 11]. In addition, there are still no established procedures regarding the use of samples and microbiological techniques. There is also the risk of contamination of the aspirate with the oral cavity flora, and in the case of absolute anaerobic bacterial overgrowth, obtaining false negative results [6]. Thus, commonly used tests in the diagnosis of SIBO, especially in the paediatric population, are indirect methods, which include hydrogen breath tests, inhalation tests with C14-labeled substances (glycocholic acid or D-xylose) and para-aminobenzoic acid test using bacterial ability to deconjugate bile acids. These are mainly non-invasive tests that are easy to perform and cheap; however, like other methods they are characterised by some limitations [6, 7, 12–15]. The main objective of therapeutic intervention in SIBO is the treatment of the primary disease, while antibiotic therapy is intended to modify intestinal microflora [5, 16–18]. An important element is nutritional supplementation, especially vital and mineral deficiencies. Abdominal pain, considered as the leading symptom in diseases of the gastrointestinal tract in children and adolescents, is one of the most common causes of diagnosing children in the hospital [19, 20]. It is considered that in the course of SIBO, bacteria actively participate in the fermentation process of disaccharides and lead to an excess of formed gases, which is associated with the feeling of distension and the presence of abdominal pain [4]. Thus, in the present study a detailed analysis of patients hospitalised due to abdominal pain was performed.

Aim

The aim of the study was the assessment of SIBO prevalence in children with abdominal pain.

Material and methods

One hundred children (59 girls and 41 boys) aged from 4 to 17 years (mean age: 10.47 ±3.73 years), hospitalised in the Department in the years 2009–2013, were enrolled in the study. In the studied group 45 children (45%) were under 10 years of age and 55 (55%) over 10 years of age. The main cause of admission to the hospital in all patients was abdominal pain, and 38 (38%) patients also had accompanying symptoms; 14 (36.9%) children presented with constipation, 11 (28.9%) nausea and/or vomiting, 6 (15.8%) diarrhoea, 4 (10.5%) fetor ex ore, and 3 patients (7.9%) presented weak or lack of weight gain. Moreover, in the studied group the place of residence in 71 (71%) children (42 (59%) girls and 29 (41%) boys) was urban, and in 29 (29%) children (17 (58.6%) girls and 12 (41.4%) boys) it was rural. The study included those patients who, during the 8 weeks preceding hospitalisation, were not subjected to antibiotic treatment. Hydrogen breath test (HBT) with lactulose (administered per os) was performed among all children as an additional test. Expired air was analysed using Gastrolyzer by Bedfont (according to the manufacturer). Expired air sample was rated fasting, and then at intervals of 15 min in the first hour and at intervals of 30 min in the second hour of the test. The initial concentration of hydrogen greater than 20 ppm (parts per million), or at least a 20 ppm increase between the maximum reading and the fasting value in the first hour of the test, was considered as a positive result. On the basis of the performed diagnostic procedures (including confirmation or exclusion of SIBO), 11 (11%) patients were additionally diagnosed with inflammation of the upper gastrointestinal tract, and 6 (6%) patients with gastro-oesophageal reflux.

Statistical analysi

Qualitative variables are presented as percentages. Continuous variables are presented as mean values with standard deviation for variables with normal distribution or as median values with interquartile range (25–75 percentiles) for variables without a normal distribution. Normal distribution was verified with Shapiro-Wilk test. Differences between groups for variables with normal distribution were analysed using the Student t test for independent couples, and for variables not normally distributed the nonparametric U Mann-Withney test was used. Analysis of categorical variables was performed using Pearson's χ2 test. Statistical analysis was performed with the use of Statistica programme 10.0PL (StatSoft, Poland). In all cases statistically significant probability of α error (p) was considered as less than 0.05.

Results

The HBT result was positive among 63 (63%) children, including 40 girls (67.8%) and 23 boys (56.1%) (Figure 1). Pearson's χ2 test showed no statistically significant differences in the incidence of SIBO in terms of gender (p = 0.23).
Figure 1

Prevalence of positive HBT result in children with abdominal pain (n = 100)

Prevalence of positive HBT result in children with abdominal pain (n = 100) Furthermore, it was also demonstrated that the child's age did not predispose to the occurrence of SIBO (p = 0.65), as shown in Figure 2.
Figure 2

Age value distribution in the studied groups – patients with positive and negative HBT result

Age value distribution in the studied groups – patients with positive and negative HBT result In the group of patients under 10 years of age, in 29 (46%) children, including 15 (23.8%) girls and 14 (22.2%) boys, the result of the test indicated small intestinal bacterial overgrowth syndrome. A similar prevalence of SIBO was observed in patients over 10 years of age. The HBT result was positive in 34 (54%) children, including 25 girls (39.7%) and 9 boys (14.3%). There was no difference in the incidence of SIBO in terms of gender in the group of younger children, up to 10 years of age. However, in the group of older children, over 10 years of age, we observed a trend towards a higher incidence of SIBO in girls (p = 0.07, χ2 test). Among 63 patients with positive HBT result, SIBO was confirmed in 26 (41.3%) patients with other accompanying symptoms next to abdominal pain, including 9 (14.3%) children with constipation, 7 (11.1%) with nausea and/or vomiting, 5 (7.9%) with a history of diarrhoea, 4 (6.4%) of all patients with fetor ex ore, and 1 (1.6%) with weight deficiency (Figure 3). The statistical analysis excluded the possibility that the presence of any of these symptoms was helpful in the diagnosis of SIBO (p = 0.4, χ2 test).
Figure 3

Prevalence of SIBO in patients with abdominal pain and other accompanying gastrointestinal symptoms (n = 100%)

Prevalence of SIBO in patients with abdominal pain and other accompanying gastrointestinal symptoms (n = 100%) On the basis of the performed diagnostic procedures 11 (11%) patients were additionally diagnosed with inflammation of the upper gastrointestinal tract. In this group, 5 (7.9% of patients with positive HBT) children obtained a positive result of HBT. The pH-metric study was suggestive of acid gastro-oesophageal reflux in 6 patients, among whom SIBO was confirmed in 3 cases (4.8% of patients with positive HBT result). In addition, the correlation between the place of residence of children (city/village) and the positive HBT result was assessed. The statistical analysis did not reveal significant differences in the prevalence of positive HBT between studied groups (p = 0.9, χ2 test). All patients with positive HBT result, suggestive of SIBO, were treated with rifaximin, a derivative of rifamycine, absorbed from the gastrointestinal tract to a very small degree. All these patients were recommended for admission to the clinic after a period of 3 months for the control of HBT. Twenty-five (39.7%) children, including 20 girls (50%) and 5 boys (21.7%) out of 63 diagnosed with SIBO, were reported for the designated control study. In this group of patients, 22 (88%), including 17 (85%) girls and 5 (100%) boys, a chieved anormal result of HBT and improvement or total withdrawal of abdominal pain. The HBT result was still positive, despite clinical improvement in 2 (10%) girls, and in 1 (5%) case HBT result was negative, while the girl still reported abdominal pain of comparable intensity and nature to that from the previous hospitalisation (Figure 4).
Figure 4

Assessment of relationship between positive or negative HBT result and symptoms in patients during 3 months after introduction of treatment (n = 25)

Assessment of relationship between positive or negative HBT result and symptoms in patients during 3 months after introduction of treatment (n = 25)

Discussion

There are a few reports in the literature on the prevalence of small intestinal bacterial overgrowth syndrome in children. The authors of most studies based the diagnosis of small intestinal bacterial overgrowth on results obtained using an indirect method: the hydrogen breath test with lactulose administered i per os [6]. However, the results of the most commonly used diagnostic test differ from the results of the study considered as the gold standard, which is microbiological evaluation of the intestinal contents [21]. This test, although easy to perform and non-invasive, above all, is also characterised by numerous limitations. The objectivity of the results is affected by factors such as bacterial flora of the oral cavity and pharynx, antibiotic therapy, the use of laxatives, a diet rich in fibre for 24 h before the test, and motor activity of the gastrointestinal tract. Accelerated intestinal transit can generate false positive results of HBT and delayed gastric emptying false negative results [3, 6]. It is worth emphasising that the definition of a positive HBT result, regardless of the substance, has not been clearly established [6]. The SIBO is characterised by a large variety of clinical pictures [22]. In the previous study, based on the analysis of chronic gastrointestinal symptoms, we showed that abdominal pain was the most common cause of admittance to hospital, as the only symptom among children (56% of total) [23]. The HBT result in this group was suggestive of SIBO in up to 70% of patients, which is similar to the current results. In the present study we confirmed the presence of SIBO in 63% of children with abdominal pain, and the prevalence of SIBO was similar in the group of children below and above 10 years of age. Hutyra et al. demonstrated positive HBT results in 54.6% of children with symptoms of constipation-predominant irritable bowel syndrome, which was statistically different compared with patients with diarrhoea-predominant type [15]. Jarząb et al. in a study on the evaluation of upper gastrointestinal tract motility disorders in children, confirmed SIBO in more than 50% of patients [24]. Lisowska et al. demonstrated SIBO prevalence in 38.7% of children and adolescents with cystic fibrosis [25]. There are also studies conducted in adults in the literature, but it is difficult to objectively compare these results with the population of children and adolescents [26, 27]. Statistical analysis revealed that the place of child residence urban/rural did not correlate with positive result of HBT. The place of residence is also not mentioned as a potential risk factor for SIBO in the available literature. All patients with positive HBT result, suggestive of SIBO, were treated with rifaximin at doses of 200 mg to 400 mg every 12 h. In the present study, we showed that in 25 patients (39.7% with positive HBT) who reported for the control study, 22 (88%) achieved a normal HBT result and significant clinical improvement. Recommendations for SIBO treatment include such antibiotics as: rifaximin, metronidazole, amoxicillin with clavulanic acid, clindamycin, ciprofloxacin, and trimethoprim with sulfamethoxazole [8, 28]. According to some authors rifaximin may be an antibiotic of choice in the treatment of SIBO, as it is slightly absorbed from the gastrointestinal tract, has relatively few side effects, and compared with other antibiotics rarely exhibits the phenomenon of resistance [14]. No studies in the literature analysing improvement of HBT after eradication treatment in the paediatric population were found. Furnari et al. showed that 87% of patients treated with this antibiotic given per os, who achieved normalisation of HBT result, simultaneously revealed clinical improvement; however, a more effective treatment proved to be the application of rifaximin with partially hydrolysed guar gum [29].

Conclusions

Small intestinal bacterial overgrowth: occurs frequently, in more than 60% of patients with abdominal pain, should be considered as one of the causes of abdominal pain in children, shows a good response to treatment.
  20 in total

1.  Small intestinal bacterial overgrowth: diagnosis and treatment.

Authors:  Antonio Gasbarrini; Ernesto Cristiano Lauritano; Maurizio Gabrielli; Emidio Scarpellini; Andrea Lupascu; Veronica Ojetti; Giovanni Gasbarrini
Journal:  Dig Dis       Date:  2007       Impact factor: 2.404

Review 2.  Review article: small intestinal bacterial overgrowth--prevalence, clinical features, current and developing diagnostic tests, and treatment.

Authors:  E Grace; C Shaw; K Whelan; H J N Andreyev
Journal:  Aliment Pharmacol Ther       Date:  2013-08-20       Impact factor: 8.171

Review 3.  Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth.

Authors:  S C Shah; L W Day; M Somsouk; J L Sewell
Journal:  Aliment Pharmacol Ther       Date:  2013-09-04       Impact factor: 8.171

4.  Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial.

Authors:  A Attar; B Flourié; J C Rambaud; C Franchisseur; P Ruszniewski; Y Bouhnik
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

Review 5.  Breath tests in the diagnosis of small intestine bacterial overgrowth.

Authors:  C E King; P P Toskes
Journal:  Crit Rev Clin Lab Sci       Date:  1984       Impact factor: 6.250

6.  Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole.

Authors:  E C Lauritano; M Gabrielli; E Scarpellini; V Ojetti; D Roccarina; A Villita; E Fiore; R Flore; A Santoliquido; P Tondi; G Gasbarrini; G Ghirlanda; A Gasbarrini
Journal:  Eur Rev Med Pharmacol Sci       Date:  2009 Mar-Apr       Impact factor: 3.507

7.  [Chosen diagnostical aspects of abdominal disorders in children].

Authors:  Krzysztof Fyderek
Journal:  Przegl Lek       Date:  2007

Review 8.  Small bowel bacterial overgrowth: presentation, diagnosis, and treatment.

Authors:  Virmeet V Singh; Phillip P Toskes
Journal:  Curr Gastroenterol Rep       Date:  2003-10

9.  [Small intestinal bacterial overgrowth in patients with functional gastrointestinal diseases].

Authors:  Ana María Madrid; Carlos Defilippi C; Claudia Defilippi G; Jocelyn Slimming A; Rodrigo Quera P
Journal:  Rev Med Chil       Date:  2007-12-20       Impact factor: 0.553

10.  Small intestinal bacterial overgrowth mimicking acute flare as a pitfall in patients with Crohn's Disease.

Authors:  Jochen Klaus; Ulrike Spaniol; Guido Adler; Richard A Mason; Max Reinshagen; Christian von Tirpitz C
Journal:  BMC Gastroenterol       Date:  2009-07-30       Impact factor: 3.067

View more
  7 in total

Review 1.  Current treatment paradigms in pediatric short bowel syndrome.

Authors:  Raghav Chandra; Anil Kesavan
Journal:  Clin J Gastroenterol       Date:  2017-12-26

2.  Is It Useful to Administer Probiotics Together With Proton Pump Inhibitors in Children With Gastroesophageal Reflux?

Authors:  Oana Belei; Laura Olariu; Andreea Dobrescu; Tamara Marcovici; Otilia Marginean
Journal:  J Neurogastroenterol Motil       Date:  2018-01-30       Impact factor: 4.924

Review 3.  Small Intestinal Bacterial Overgrowth in Children: A State-Of-The-Art Review.

Authors:  David Avelar Rodriguez; Paul MacDaragh Ryan; Erick Manuel Toro Monjaraz; Jaime Alfonso Ramirez Mayans; Eamonn Martin Quigley
Journal:  Front Pediatr       Date:  2019-09-04       Impact factor: 3.418

4.  Small intestinal bacterial overgrowth in children with intestinal failure on home parenteral nutrition.

Authors:  Kathleen H McGrath; James Pitt; Julie E Bines
Journal:  JGH Open       Date:  2019-04-04

5.  Role of Glucose Breath Test for Small Intestinal Bacterial Overgrowth in Children and Adolescents With Functional Abdominal Pain Disorders in Korea.

Authors:  Jin Lee; Chang-Nyol Paik; Dae Bum Kim; Ji Min Lee; Yeon-Ji Kim; Sik Kyung Choi; Yeon Jong Cho
Journal:  J Neurogastroenterol Motil       Date:  2022-01-30       Impact factor: 4.924

6.  Is it bowel-associated dermatosis-arthritis syndrome induced by small intestinal bacteria overgrowth?

Authors:  Hongjun Zhao; Lijuan Zhao; Wei Shi; Hui Luo; Liping Duan; Yunhui You; Yisha Li; Xiaoxia Zuo
Journal:  Springerplus       Date:  2016-09-13

7.  Outcome of breath tests in adult patients with suspected small intestinal bacterial overgrowth.

Authors:  Johanna Mattsson; Maria Teresa Minaya; Milka Monegro; Benjamin Lebwohl; Suzanne K Lewis; Peter Hr Green; Reidun Stenberg
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2017
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.